Zura Bio (NASDAQ:ZURA) Research Coverage Started at HC Wainwright

HC Wainwright initiated coverage on shares of Zura Bio (NASDAQ:ZURA) in a report issued on Thursday, MarketBeat.com reports. The firm issued a neutral rating and a $5.00 price objective on the stock.

A number of other research firms have also recently commented on ZURA. Cantor Fitzgerald reissued an overweight rating on shares of Zura Bio in a report on Thursday, August 15th. Oppenheimer increased their target price on shares of Zura Bio from $16.00 to $21.00 and gave the stock an outperform rating in a report on Friday, May 10th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Zura Bio has a consensus rating of Moderate Buy and a consensus price target of $15.50.

Zura Bio Stock Down 4.0 %

NASDAQ:ZURA opened at $3.62 on Thursday. Zura Bio has a 52 week low of $2.00 and a 52 week high of $7.22. The firm’s 50-day simple moving average is $3.69 and its 200 day simple moving average is $3.77.

Zura Bio (NASDAQ:ZURA) last issued its earnings results on Tuesday, August 13th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Research analysts expect that Zura Bio will post -0.53 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Someit Sidhu sold 51,728 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total value of $200,187.36. Following the sale, the director now owns 2,085,418 shares of the company’s stock, valued at $8,070,567.66. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 15.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Zura Bio

Institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC raised its stake in Zura Bio by 51.3% during the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock worth $61,000 after buying an additional 5,900 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Zura Bio by 15.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock worth $165,000 after acquiring an additional 6,412 shares in the last quarter. Forefront Analytics LLC lifted its stake in shares of Zura Bio by 46.8% in the 4th quarter. Forefront Analytics LLC now owns 21,229 shares of the company’s stock valued at $99,000 after purchasing an additional 6,765 shares during the period. AQR Capital Management LLC bought a new stake in shares of Zura Bio during the 2nd quarter valued at about $43,000. Finally, Armistice Capital LLC grew its position in shares of Zura Bio by 15.4% during the 4th quarter. Armistice Capital LLC now owns 1,824,000 shares of the company’s stock worth $8,518,000 after buying an additional 244,000 shares during the period. 61.14% of the stock is owned by institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.